Previous 10 |
home / stock / eprxf / eprxf news
Eupraxia Pharmaceuticals press release (OTCPK:EPRXF): Q1 net loss of $3.8 million for the three months ended March 31, 2022, versus $8.9 million for the quarter ended March 31, 2021. The Company had a cash and short-term investments balance of $25.9 million as at March 31, 2022. Management be...
News, Short Squeeze, Breakout and More Instantly...
Eupraxia Pharmaceuticals Company Name:
EPRXF Stock Symbol:
OTCMKTS Market:
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 15, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has closed i...
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has priced i...
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced the launch of an ove...